专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

US20010018435A1 Steroid sulphatase inhibitors 失效
标题翻译：类固醇硫酸酶抑制剂
公开(公告)号：US20010018435A1
公开(公告)日：2001-08-30
申请号：US09794853
申请日：2001-02-27
申请人： STERIX LIMITED
发明人： Michael John Reed , Barry Victor Lloyd Potter
IPC分类号： A61K031/565 , A61K031/18
CPC分类号： A61K31/37 , C07D311/16 , C07D311/30 , C07D311/32 , C07D311/36 , C07J41/0072
摘要： A method of inhibiting steroid sulphatase activity in a subject in need of same is described. The method comprises administering to said subject a steroid sulphatase inhibiting amount of a ring system compound; which ring system compound comprises a ring to which is attached a sulphamate group of the formula 1 wherein each of R1 and R2 is independently selected from H, alkyl, alkenyl, cycloalkyl and aryl, or together represent allylene optionally containing one or more hetero atoms or groups in the alkylene chain; and wherein said compound is an inhibitor of an enzyme having steroid suiphatase activity (E.C.3.1.6.2); and if the sulphamate group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at a pH 7.4 and 37null C. it would provide a Km value of less tha 50 nullM.
摘要翻译：描述了在需要相同的受试者中抑制类固醇硫酸酯酶活性的方法。所述方法包括向所述受试者施用抑制甾族硫酸酯酶的量的环系化合物; 该环系化合物包含连接下式的氨基磺酸酯基的环，其中R 1和R 2各自独立地选自H，烷基，烯基，环烷基和芳基，或一起表示任选含有一个或多个杂原子或基团的烯丙基在亚烷基链中; 并且其中所述化合物是具有类固醇脂肪酶活性的酶的抑制剂（E.C.3.1.6.2）; 并且如果所述化合物的氨基磺酸酯基团被硫酸根基团取代以形成硫酸盐化合物，并在pH 7.4和37℃下与类固醇硫酸酶（EC3.1.6.2）一起温育，则其将提供小于50的Km值 muM

3. 发明申请

WO2007096647A2 COMPOUND 审中-公开
标题翻译：复合
公开(公告)号：WO2007096647A2
公开(公告)日：2007-08-30
申请号：PCT/GB2007/000655
申请日：2007-02-26
申请人： STERIX LIMITED , VICKER, Nigel , ALLAN, Gillian, Margaret , LAWRENCE, Harshani, Rithma, Ruchiranani , DAY, Joanna, Mary , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
发明人： VICKER, Nigel , ALLAN, Gillian, Margaret , LAWRENCE, Harshani, Rithma, Ruchiranani , DAY, Joanna, Mary , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
IPC分类号： C07D213/75 , C07C49/757 , C07D231/54 , C07D213/40 , C07D231/12 , C07D261/08 , C07D277/40 , C07D307/52 , C07C255/40 , C07D231/14 , C07D231/38 , C07D307/60 , C07C43/205 , C07C43/275 , C07D317/54
CPC分类号： C07C323/22 , C07C37/62 , C07C45/00 , C07C45/46 , C07C45/673 , C07C45/68 , C07C45/71 , C07C49/747 , C07C49/753 , C07C49/755 , C07C49/757 , C07C49/83 , C07C49/84 , C07C49/86 , C07C59/90 , C07C69/712 , C07C69/738 , C07C235/74 , C07C235/78 , C07C235/84 , C07C255/40 , C07C2602/08 , C07C2602/10 , C07D213/40 , C07D213/75 , C07D231/12 , C07D231/38 , C07D241/12 , C07D261/08 , C07D277/40 , C07D317/54 , C07D401/12 , C07C39/367
摘要： There is provided a compound of Formula (I): wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , and R 10 , are independently selected from -H, -OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (-CN), nitro (-NO 2 ), and halogens; wherein ring A is optionally further substituted wherein X is a bond or a linker group wherein (A) (i) R 9 is selected from alkyl and halogen groups; and (ii) R10 is selected from -OH, oxyhydrocarbyl and -OSO 2 NR 1 R 2 ; wherein R 1 and R 2 are independently selected from H and hydrocarbyl or (B) at least one of R 3 , R 4 , R 5 , R 6 and R 7 is the group -C(=0)-CR 11 R 12 -R 8 wherein R 8 is a selected from (i) an alkyloxyalkyl group (ii) a nitrile group, (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group wherein the aryl group is substituted (v) alkylheteroaryl group, wherein when heteroaryl group comprises only C and N in the ring, the aryl group is substituted by other than a methyl group (vi) alkenylheteroaryl group (vii) =N-O-alkyl or =N-O-H group (viii) branched alkenyl (ix) alkyl-alcohol group or alkenyl-alcohol group (x) amide or alkylamide wherein (a) the alkyl of the alkylamide is -CH 2 - or - CH 2 CH 2 -, (b) the amide is di-substituted and/or (c) the amide is substituted with at least one of alkylheterocycle group, alkenylheterocycle group, alkylheteroaryl group, alkenylheteroaryl group, heteroaryl group, alkylamine group, alkyloxyalkyl group, alkylaryl group, straight or branched alkyl group, (xi) -CHO, or together with another of R 3 , R 4 , R 5 , R 6 and R 7 the enol tautomer thereof wherein R 11 and R 12 are independently selected from H and hydrocarbyl; or (C) at least one of R 3 , R 4 , R 5 , R 6 and R 7 together with another of R 3 , R 4 , R 5 , R 6 and R 7 forms a ring containing -C(=O)-; or (D) at least one of R 3 , R 4 , R 5 , R 6 and R 7 is selected from alkylheterocycle group, alkenylheterocycle group, alkylheteroaryl group, alkenylheteroaryl group, and heteroaryl groups or (E) at least one of R 3 , R 4 , R 5 , R 6 and R 7 is selected from -CN, -C(R 13 )=N-O-alkyl group, - C(R 14 )=N-O-H group, optionally substituted pyrazole, optionally substituted thiazole, optionally substituted oxazole, optionally substituted isoxazole, optionally substituted pyridine, and optionally substituted pyrimidine, or together with another of R 3 , R 4 , R 5 , R 6 and R 7 forms a nitrogen containing ring; wherein R 13 and R 14 are independently selected from H and hydrocarbyl.
摘要翻译：提供式（I）的化合物：其中R 3，R 4，R 5，R 6，/ R 7，R 9和R 10独立地选自-H，-OH，烃基，羟基烃基，氰基（-CN），硝基（-NO 2 N 2）和卤素; 其中环A任选进一步被取代，其中X是键或连接基团，其中（A）（i）R 9选自烷基和卤素基团; 和（ii）R 10选自-OH，羟基烃基和-OSO 2 NR 1 R 2 R 2。其中R 1和R 2独立地选自H和烃基或（B）R 3，R 4中的至少一个 R 5，R 6和R 7是基团-C（= O）-CR 11，其中R 8选自（ⅰ）烷氧基烷基（ⅱ）腈基，（ⅰ） iii）烷基芳基，其中芳基被除了其中芳基被取代的（C 1 -C 6）烯基芳基以外的其它取代基取代（v）烷基杂芳基，其中当杂芳基仅在环中仅包含C和N时，芳基被甲基除外（vi）烯基杂芳基（vii）= NO-烷基或= NOH基（viii）支链烯基（ix）烷基醇基或链烯基（x）酰胺或烷基酰胺，其中（a）烷基酰胺的烷基是-CH 2 - 或 - CH 2 CH 2 - ，（b）酰胺是二 - 取代和/或（c）酰胺被至少一个烷基取代烯基杂环基，烷基杂芳基，烯基杂芳基，杂芳基，烷基胺基，烷氧基烷基，烷基芳基，直链或支链烷基，（xi）-CHO，或与另一个R 3 R 4，R 5，R 6和R 7其烯醇互变异构体，其中R 11 R 12和R 12独立地选自H和烃基; 或（C）R 3，R 4，R 5，R 6和R 6中的至少一个，与R 3，R 4，R 5，R 6，R 6，R 5，R 5，和R 7形成含有-C（= O） - 的环; 或（D）R 3，R 4，R 5，R 6和R 6中的至少一个，选自烷基杂环基，烯基杂环基，烷基杂芳基，烯基杂芳基和杂芳基，或（E）R 3，R 4中的至少一个， R 5，R 6，R 7和R 7选自-CN，-C（R 13））= NO-烷基，-C（R 14）= NOH基，任选取代的吡唑，任选取代的噻唑，任选取代的恶唑，任选取代的异恶唑，任选取代的吡啶和任选取代的嘧啶，或与R 3，R 4，R 5，R 6和R 7中的另一个一起， / SUB>形成含氮环; 其中R 13和R 14独立地选自H和烃基。

4. 发明申请

WO2007068905A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS 审中-公开
标题翻译：用于治疗依靠内肿瘤的肿瘤的1,2,4-三唑-1-基联苯衍生物
公开(公告)号：WO2007068905A1
公开(公告)日：2007-06-21
申请号：PCT/GB2006/004630
申请日：2006-12-12
申请人： STERIX LIMITED , WOO, Lok, Wai, Lawrence , JACKSON, Toby , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
发明人： WOO, Lok, Wai, Lawrence , JACKSON, Toby , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
IPC分类号： C07D249/08 , C07D405/10 , A61K31/4196 , A61P35/00
CPC分类号： C07D249/08 , C07D405/10
摘要： There is provided a compound of Formula I wherein R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from H and -Y-R 6 ; wherein each R 8 is independently selected from -OH, hydrocarbyl groups, oxyhydrocarbyl groups, cyano (-CN), nitro (-NO 2 ), H-bond acceptors, and halogens; wherein at Jeast one of R 3 , R 4 , R 5 , R 6 and R 7 is -Y-R 8 wherein R 8 is selected from substituted and unsubstituted • heterocyclic rings and amino substituted phenyl groups, wherein X is a bond or a linker group; wherein Y is an optional linker group; and wherein ring A is optionally further , substituted; wherein R 9 is selected from H, -OH and -OSO 2 NR 1 R 2 ; wherein R1 and R2 are independently selected from H and hydrocarbyl; wherein (a) X is a bond and at least one of R 3 , R 4 , R 5 , R 6 and R 7 is -Y-R 8 ; OR (b) R 9 is -OSO 2 NR 1 R 2 or - OH and four of R 3 , R 4 , R 5 , R 6 and R 7 are H and one of R 3 , R 4 , R 5 , R 6 and R 7 is -Y-R 8 . These compounds inhibit steroid sulphatase and aronatase activity and are useful in the treatment of endocrine-dependent tumours.
摘要翻译：提供式I的化合物，其中R 3，R 4，R 5，R 6和R 3 7个独立地选自H和-YR 6; 其中每个R 8独立地选自-OH，烃基，羟基烃基，氰基（-CN），硝基（-NO 2 H 2），H键受体和卤素; 其中在R 3 R 3，R 4，R 5，R 6和R 7的每一个其中R 8选自取代和未取代的杂环和氨基取代的苯基，其中X是键或连接基团;其中R 8选自取代和未取代的杂环和氨基取代的苯基。其中Y是任选的连接基团; 并且其中环A任选进一步被取代; 其中R 9选自H，-OH和-OSO 2 NR 1 R 2; 其中R1和R2独立地选自H和烃基; 其中（a）X是一个键，R 3，R 4，R 5，R 6， R 3和R 7是-YR 8; OR（b）R 9是-OSO 2 NR 1 R 2 R 2或 - OH，R 4中的四个 R 3，R 4，R 5，R 6和R 7均为H和 R 3，R 4，R 5，R 6和R 7中的一个，是-YR <8> 。这些化合物抑制类固醇硫酸酯酶和aronatase活性，并且可用于治疗内分泌依赖性肿瘤。

5. 发明申请

WO2006100502A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS 审中-公开
标题翻译： 11-β-羟基脱氢酶抑制剂
公开(公告)号：WO2006100502A1
公开(公告)日：2006-09-28
申请号：PCT/GB2006/001086
申请日：2006-03-23
申请人： STERIX LIMITED , VICKER, Nigel , SU, Xiangdong , PRADAUX, Fabienne , REED, Michael, John , POTTER, Barry, Victor, Lloyd
发明人： VICKER, Nigel , SU, Xiangdong , PRADAUX, Fabienne , REED, Michael, John , POTTER, Barry, Victor, Lloyd
IPC分类号： C07D277/64 , C07D277/20 , C07D213/56 , C07D213/86 , C07D333/24 , C07D239/26 , C07D233/64 , C07D271/06 , C07C233/57 , C07C317/14 , A61K31/381 , A61K31/16 , A61K31/18 , A61P3/00
CPC分类号： C07C233/25 , C07C233/58 , C07C233/59 , C07C311/13 , C07C311/16 , C07C311/20 , C07C317/24 , C07C323/22 , C07C2603/74 , C07D207/09 , C07D207/335 , C07D209/14 , C07D213/40 , C07D213/75 , C07D213/82 , C07D233/24 , C07D233/54 , C07D233/64 , C07D239/26 , C07D271/06 , C07D277/20 , C07D277/64 , C07D295/13 , C07D307/52 , C07D333/20 , C07D333/34 , C07D333/58
摘要： There is provided a compound having Formula (I ) R 1 -Z-R 2 wherein R 1 is a group selected from optionally substituted fused polycyclic groups, substituted alkyl groups, branched alkyl groups, and optionally substituted cycioalkyl groups Z is a linker which is or comprises a carbonyl group or a isostere of a carbonyl group R 2 is selected from optionally substituted aromatic rings and optionally substituted heterocyclic rings wherein (a) R 2 is a 2-substituted thiophene group, and/or (b) Z is a group of the formula -C(=O)-CR 3 R 4 -X-(CR 5 R 6 )n-, wherein X is selected from NR 7 , S, O, S=O, and S(=O) 2 , wherein n is 0 or 1 and/or (c) R 1 is an adamantyl group and Z is or comprises an amide group, and/or (d) R 1 is an adamantyl group and Z is or comprises a group of the formula -(CR 8 R 9 )p- NR 10 -S(=O) 2 -(CR 11 R 12 )q-, wherein p is 0 or 1 and q is 0 or 1 and/or (e) R 1 is an adamantyl group and Z is or comprises a group of the formula -(CR 13 R 14 )V-Y- (CR 15 R 16 )W- where Y is a heteroaryl group in which a bond in the heteroaryl ring is a isostere of a carbonyl group, wherein v is o or 1 and w is 0 or 1 ; wherein each of R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 , are independently selected from H, hydrocarbyl and halogen, wherein each of R 7 and R 10 are independently selected from H and hydrocarbyl.
摘要翻译：提供具有式（I）R 1 -ZR 2的化合物，其中R 1是选自任选取代的稠合多环基团，取代的烷基，支链烷基和任选取代的环烷基Z是作为或包含羰基或羰基的等排物的连接基R 2 2选自任选取代的芳环和任选取代的杂环，其中（a）R 2是2-取代的噻吩基团，和/或（b）Z是式-C（= O）-CR 3的基团，其中X选自NR 7 N， - （CR 5 R 6）n - ，其中X选自NR 7 >，S，O，S = O和S（= O）2，其中n为0或1，和/或（c）R 1为金刚烷基并且Z是或包含酰胺基，和/或（d）R 1是金刚烷基，Z是或包含下式的基团 - （CR 8 R 13）对 - NR 10 -S（= O）2 - （CR 11 R 13） q-，其中p是0或1，q是0或1，和/或（e）R 1是金刚烷基，Z是或包含一个式 - （CR 13 R 14）V Y - （CR 15 R 16）W - 其中Y是杂芳基环中的键为羰基的等排基团的杂芳基，其中v为0或1，w为0或1; 其中R 3，R 4，R 5，R 6，R 8， R 9，R 11，R 12，R 13，R 14， R 15，R 16和R 16独立地选自H，烃基和卤素，其中R 7和R 15各自独立地选自氢， 10个独立地选自H和烃基。

6. 发明申请

WO2004037251A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 审中-公开
标题翻译： 11-羟基甾体脱氢脱氢酶1型和2型的抑制剂
公开(公告)号：WO2004037251A1
公开(公告)日：2004-05-06
申请号：PCT/GB2003/004590
申请日：2003-10-23
申请人： STERIX LIMITED , VICKER, Nigel , SU, Xiangdong , GANESHAPILLAI, Dharshini , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
发明人： VICKER, Nigel , SU, Xiangdong , GANESHAPILLAI, Dharshini , PUROHIT, Atul , REED, Michael, John , POTTER, Barry, Victor, Lloyd
IPC分类号： A61K31/428
CPC分类号： C07D263/56 , C07D209/08 , C07D209/42 , C07D235/08 , C07D235/10 , C07D277/64 , C07D277/68 , C07D277/74 , C07D277/82
摘要： There is provided a compound having Formula (I): wherein one of R 1 and R 2 is a group of the Formula (a), wherein R 4 is selected from H and hydrocarbyl, R 5 is a hydrocarbyl group and L is an optional linker group, or R 1 and R 2 together form a ring substituted with the group (Formula (a)) wherein R 3 is H or a substituent, and wherein X is selected from S, O, NR 6 and C(R 7 )(R 8 ), wherein R 6 is selected from H and hydrocarbyl groups, wherein each of R 7 and R 8 are independently selected from H and hydrocarbyl groups.
摘要翻译：提供具有式（I）的化合物：其中R 1和R 2之一是式（a）的基团，其中R 4选自H和烃基，R 5是烃基，L是任选的连接基团，或 R 1和R 2一起形成被其中R 3为H或取代基的基团（式（a））取代的环，其中X选自S，O，NR 6和C（R 7）（R 8），其中R 6选自 H和烃基，其中R 7和R 8各自独立地选自H和烃基。

7. 发明申请

WO2002098511A1 COMPOSITIONS COMPRISING OESTRONE-3-0-SULPHAMATE AND TRAIL (TNF-RELATED APOPTOSIS INDUCING LIGAND) 审中-公开
标题翻译：包含OESTRONE-3-0-磺酰胺和TRAIL（与TNF相关的药物诱导配体）的组合物
公开(公告)号：WO2002098511A1
公开(公告)日：2002-12-12
申请号：PCT/GB2002/002541
申请日：2002-06-06
申请人： STERIX LIMITED , PACKHAM, Graham, Keith , REED, Michael, John , POTTER, Barry, Victor, Lloyd
发明人： PACKHAM, Graham, Keith , REED, Michael, John , POTTER, Barry, Victor, Lloyd
IPC分类号： A61P35/00
CPC分类号： A61K45/06 , A61K31/565 , A61K38/177 , Y02A50/465 , A61K2300/00
摘要： The present invention provides a composition comprising (i) a compound comprising a sulphamate group ("a sulphamate compound"); and (ii) an apoptosis inducer.
摘要翻译：本发明提供一种组合物，其包含（i）包含氨基磺酸酯基团（“氨基磺酸盐化合物”）的化合物; 和（ii）凋亡诱导剂。

8. 发明专利

TR200100070A3 Bilesim 未知
公开(公告)号：TR200100070A3
公开(公告)日：2001-08-21
申请号：TR200100070
申请日：2001-01-11
申请人： STERIX LIMITED , SCHERING AKTIENGESELLSCHAFT
发明人： BARRY VICTOR LLOYD POTTER , MICHAEL JOHN REED , WALTER ELGER , GUDRUN RODDERSEN , HEINRICH-THOMAS PROSKE
IPC分类号： A61K45/00 , A61K31/56 , A61K31/565 , A61K31/567 , A61P5/30 , A61P15/00 , A61P15/18 , A61P43/00 , C07J1/00 , C07J7/00 , A61K31/566 , A61K31/5685

9. 发明申请

WO2007099304A1 STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS 审中-公开
标题翻译： STEROIDAL化合物作为固体硫酸酯酶抑制剂
公开(公告)号：WO2007099304A1
公开(公告)日：2007-09-07
申请号：PCT/GB2007/000686
申请日：2007-02-28
申请人： STERIX LIMITED , POTTER, Barry, Victor, Lloyd , REED, Michael, John , WOO, Lok, Wai, Lawrence , PUROHIT, Atul , FOSTER, Paul
发明人： POTTER, Barry, Victor, Lloyd , REED, Michael, John , WOO, Lok, Wai, Lawrence , PUROHIT, Atul , FOSTER, Paul
IPC分类号： C07J63/00 , A61K31/56 , A61P35/00
CPC分类号： C07J63/00
摘要： There is provided a compound having Formula (I): wherein G is a fluorocarbyl group, and wherein R 1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group, capable of inhibiting steroid sulphatase.
摘要翻译：提供具有式（I）的化合物：其中G是氟代羰基，并且其中R 1是氨基磺酸酯基，膦酸酯基，硫代膦酸酯基，磺酸酯基或磺胺类，能够抑制类固醇硫酸酯酶。

10. 发明申请

WO2006032885A2 COMPOUND 审中-公开
标题翻译：复合
公开(公告)号：WO2006032885A2
公开(公告)日：2006-03-30
申请号：PCT/GB2005/003641
申请日：2005-09-21
申请人： STERIX LIMITED , LEESE, Mathew , PUROHIT, Alan , REED, Michael, John , JOURDAN, Fabrice , POTTER, Barry, Victor, Lloyd , BURBERT, Christian
发明人： LEESE, Mathew , PUROHIT, Alan , REED, Michael, John , JOURDAN, Fabrice , POTTER, Barry, Victor, Lloyd , BURBERT, Christian
IPC分类号： C07J41/00 , C07J43/00 , C07J31/00 , C07J3/00 , C07J7/00 , A61K31/565 , A61K31/566 , A61K31/57 , A61K31/58 , A61P5/32
CPC分类号： C07J43/003 , C07J3/00 , C07J7/0005 , C07J31/006 , C07J41/0005 , C07J41/0072
摘要： The present invention provides a compound comprising a steroidal ring system and an optional group R 1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein the A ring of the steroidal ring system is optionally substituted at position 2 or 4 with a group R 4 which may be a suitable subtituent wherein the D ring of the steroidal ring system is substituted by a group R 2 of the formula -L-R 3 , wherein L is an optional linker group and R 3 is selected from groups which are or which comprise one of (i) -S0 2 R 5 , wherein R 5 is H, a hydrocarbyl group or a bond or group attached to the D ring; (ii) -NO 2 ; (iii) -SOR 6 , wherein R 6 is H or a hydrocarbyl group; (iv) -R 7 , wherein R 7 is a halogen; (v) - alkyl; (vi) -C(=O)R 8 , wherein R 8 is H or hydrocarbyl; (vii) -C≡CR 9 , wherein R 9 is H or hydrocarbyl; (viii) -OC(=O)NR 10 R 11 wherein R 10 and R 11 are independently selected from H and hydrocarbyl; (ix), (x), (xi), (xii) and (xiii) are formulae wherein when R 3 is -alkyl, R 4 is present as a hydrocarbon group, when R 3 is -NO 2 R 4 is present and/or R 1 is present as a sulphamate group, and when R 3 is -C(=O)R 8 R 4 is present and R 1 is present as a sulphamate group.
摘要翻译：本发明提供了包含选自-OH，氨基磺酸酯基，膦酸酯基，硫代膦酸酯基，磺酸酯基或磺酰胺中的任何一种的甾体环系和任选的基团R 1的化合物组; 其中所述甾族环系统的A环任选在位置2或4处被基团R 4取代，所述基团R 4可以是合适的取代基，其中所述甾族环系统的D环被基团R 其中L是任选的连接基团，R 3选自以下基团：其中R 1，R 2，R 3，（i）-S 0 2 R 5，其中R 5是H，连接到D环的烃基或键或基团; （ii）-NO 2 2; （iii）-SOR 6，其中R 6是H或烃基; （iv）-R 7，其中R 7为卤素; （ⅴ） - 烷基; （vi）-C（= O）R 8，其中R 8为H或烃基; （vii）-C = CR 9，其中R 9是H或烃基; （viii）-OC（= O）NR 10 R 11，其中R 10和R 11独立地选自由H和烃基组成; （ix），（x），（xi），（xii）和（xiii）是其中当R 3为 - 烷基时，R 4为烃，当R 3为-NO 2 R 4存在时，和/或R 1存在作为并且当R 3为-C（= O）时，存在R 8 R 4和R 4，并且R 1〜 >以氨基磺酸盐基团存在。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式